Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that testosterone-enanthate increased red blood cell production and altered iron homeostasis in older hypogonadal men without being affected by finasteride, indicating these effects do not require type II 5α-reductase enzyme activity.

This study found that high TSPEAR expression in colorectal cancer was associated with poor prognosis and correlated with various tumor and immune-related factors.

In this case report, tofacitinib was initiated in a 20-year-old female with alopecia universalis resistant to topical treatments, but resulted in a mild peripheral neuropathy side effect.

In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.

In this study, researchers found that the loss of SETDB1 in epidermal keratinocytes led to altered chromatin states, increased ERV expression, and activation of immune responses, while inhibiting these effects with certain antiviral drugs reduced skin inflammation and hair loss in a mouse model.

In this report, a 61-year-old woman with vitiligo showed significant improvement after tofacitinib treatment but developed lung adenocarcinoma, highlighting potential cancer risks associated with JAK inhibitors.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

This study found that applying 2.5% testosterone gel increased facial terminal hairs in young males with beta-thalassemia major and was well tolerated.

This study found that approximately one-quarter of post-COVID-19 patients experienced telogen effluvium, with a higher incidence among women, hospitalized patients, and those with hypertension or respiratory symptoms.

This study analyzed pexidartinib-associated adverse events from FDA data and reported common events such as hepatic issues and systemic reactions. It highlighted sex-specific susceptibilities and reinforced the need for risk mitigation and long-term monitoring in tenosynovial giant cell tumor management.

This consensus paper reviews expert opinions on treating telogen effluvium but reports no new clinical findings.

This study suggests that IT PEP injection may have beneficial effects after spinal cord injury, but additional research is necessary to better understand and optimize its clinical application.

This review found that tea tree oil, especially terpinen-4-ol, may be the most effective treatment for Demodex-related diseases, but more research is needed to improve treatment efficacy and reduce side effects.

This review article explores the current use and evidence of stem cell therapy in dermatology, detailing its applications, benefits, and limitations across various skin disorders, while also addressing teledermatology's rise during COVID-19 and proposing its ongoing integration into healthcare delivery.

This study found that patients with telogen effluvium had significantly lower serum ferritin levels compared to healthy controls, suggesting a relationship between telogen effluvium and decreased iron stores.

The researchers reported that COVID-induced telogen effluvium can occur after both severe and mild infections, potentially presenting earlier than other causes, and necessitates specific patient management due to its psychological impact.

This study found that patients with telogen effluvium had a higher quality of life score compared to controls, despite no significant difference in self-esteem.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.

This review reports limited evidence on topical treatments for beard enhancement, with topical minoxidil, testosterone gel, and tretinoin showing potential but requiring further study.

This research demonstrates that a temperature controllable medical chilling device using thermal electric cooling technology effectively maintains constant cell temperatures, potentially improving tissue viability during hair transplant procedures.

This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.

This study found that long-term weekly administration of docetaxel is feasible at doses up to 45 mg/m² per week with acceptable toxicity, and suggests further evaluation with 40 mg/m² for phase II studies.

This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.

This study involving 126 patients found that tofacitinib has high effectiveness and an acceptable safety profile for treating alopecia areata, with a 33.8% complete response rate at 24 weeks and sex as an independent risk factor for outcomes.

In this experimental study, researchers found that intravitreal injections of up to 100μg of topotecan in rabbits caused no systemic or ocular toxicity, while 200μg doses resulted in localized retinal changes and decreased electroretinography amplitudes near the injection site.

This study observed initial hair regrowth in a businessman with alopecia areata universalis treated with tofacitinib, but the effect diminished, leading to renewed hair loss.

This study found that telogen effluvium, a temporary hair loss condition, is significantly associated with COVID-19 recovery, particularly affecting females.

This study found that combining 308-excimer phototherapy with intramuscular triamcinolone acetonide was effective and well tolerated for treating resistant alopecia totalis, showing a 90% overall response rate in the ten patients studied, with the best results observed in younger patients.